Compare ADMA Biologics Inc (ADMA) vs Aptiv PLC (APTV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Aptiv PLC — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Aptiv PLC trades at $57.63 (market cap $12.45B). The key difference: Aptiv PLC is far larger — about 5.8× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | APTV | |
|---|---|---|
Market Cap | $2.13B | $12.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $76.82 |
52-Week Low | $7.60 | $52.57 |
Enterprise Value | $2.20B | $19.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
APTV trades at $58.85, down 0.07% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.71, exceeding expectations of $1.62. Revenue for 2025 reached $20.40B with a net income margin of 1.77%. Analyst consensus is strongly bullish with a $80.67 price target, though technical indicators show selling pressure with support at $58.
The outlook remains mixed: strong analyst support and solid cash flow trends contrast with narrow profit margins and bearish technicals. Key risks include margin compression and high debt levels, but institutional sentiment suggests potential upside if earnings momentum continues through Q2 results on August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →
